Healthcare - Biotechnology - NASDAQ - US
$ 0.3397
-2.92 %
$ 5.87 M
Market Cap
0.0
P/E
CASH FLOW STATEMENT
-18.1 M
OPERATING CASH FLOW
-35.6 K
INVESTING CASH FLOW
15.9 M
FINANCING CASH FLOW
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
TransCode Therapeutics, Inc.
| Net Income | -18.5 M |
| Depreciation & Amortization | 517 K |
| Capital Expenditures | -35.6 K |
| Stock-Based Compensation | 1.04 M |
| Change in Working Capital | -1.08 M |
| Others | -146 K |
| Free Cash Flow | -18.1 M |
Cash Flow
Millions
| Dec-2023 | Dec-2022 | Dec-2021 | Dec-2020 | Dec-2019 | Dec-2018 | |
|---|---|---|---|---|---|---|
| OPERATING CASH FLOW | ||||||
| Net Income | (18.5) | (17.6) | (6.8) | (2.3) | (0.6) | (0.5) |
| Depreciation & Amortization | 0.5 | 98.6 K | 42.5 K | 0 | 0 | 0 |
| Deferred Income Tax | 0 | 0.9 | 0.9 | 0 | 0 | 0 |
| Stock Based Compensation | 1.0 | 0.4 | 0.2 | 45.4 K | 1.4 K | 22.4 K |
| Other Operating Activities | 0 | (0.9) | 39.5 K | 1.5 | 0.1 | 0.1 |
| Change in Working Capital | (1.1) | 1.3 | 0.4 | 0.3 | 4.7 K | 24.9 K |
| Cash From Operations | (18.1) | (15.8) | (5.3) | (0.5) | (0.5) | (0.3) |
| INVESTING CASH FLOW | ||||||
| Capital Expenditures | 35.6 K | (0.1) | (0.3) | 0 | 0 | 0 |
| Other Items | 0 | 0 | 3 K | 0 | 0 | 0 |
| Cash From Investing Activities | 35.6 K | (0.1) | (0.3) | 0 | 0 | 0 |
| FINANCING CASH FLOW | ||||||
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Debt Repaid | 0 | 0 | 0 | 1.2 | 0.5 | 0.6 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 0 | 5.99 K | (0.8) | 73.5 K | 0 | 37.6 K |
| Cash From Financing Activities | 15.9 | 5.99 K | 25.5 | 1.1 | 0.5 | 0.5 |
| CHANGE IN CASH | ||||||
| Net Change In Cash | (2.2) | (15.9) | 20.0 | 0.6 | 8.51 K | 0.2 |
| FREE CASH FLOW | ||||||
| Free Cash Flow | (18.1) | (15.9) | (5.5) | (0.5) | (0.5) | (0.3) |